PRIMO Honors the 2018 Recipients of the Women in Oncology Award

Today, concluding the second day of the Third Annual Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Meeting, the Women in Oncology Awards were presented. This award is granted to three eminent women in the fields of academia, advocacy, and industry, and whose work has led to the betterment of the lives of cancer patients and their families.

 

And the winners of the 2018 Women in Oncology Award are:

 

For Academia: Monica M. Bertagnolli, MD.

Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the field of Surgical Oncology at Harvard Medical School. She is the Chief of the Division of Surgical Oncology at Dana Farber/Brigham and Women’s Cancer Center, where she also serves as a member of the Gastrointestinal Cancer and Sarcoma Disease Centers. Her research has focused on the role of inflammatory response in epithelial tumor formation. She has performed as a leader in her communities, currently acting as the Group Chair of the Alliance for Clinical Trials in Oncology, as well as the Chief Executive Officer of Alliance Foundation Trials, LLC, a non-profit organization conducting cancer clinical trials. This June, she will begin her term as the President of the American Society of Clinical Oncology.

 

For Industry, Alise Reicin, MD.

Dr. Reicin is the Senior Vice President, Head of Global Clinical Development, for Merck. She oversees Clinical Therapeutic Areas, Statistics, Evidence and Value Development, and Clinical Operations. She has extensive experience in therapeutic areas, including oncology and immunology. In her role as Vice President, Project and Pipeline Leadership, Oncology Franchise at Merck Sharp & Dohme, she led the PD-1 program and saw it from initial development and filing to the late-stage development plans. Over the course of her career, she has been dealt a great deal of responsibility in R&D, working as Vice President in Strategic Realization Office, the Head of a Transformation Task Force for late clinical development, and many other roles.

 

For Advocacy, Ellen V. Sigal, PhD.

Dr. Sigal is the Chairperson and Founder of Friends of Cancer Research in Washington, D.C., an organization dedicated to advancements in science, policy, and regulation to increase the speed of life-saving treatments for patients. She is also the Chair of the Reagan-Udall Foundation, which works with the Food and Drug Administration to accelerate innovation and enhance product safety. In 2016, she served on Vice President Biden’s Cancer Moonshot Blue Ribbon Panel, the Parker Institute for Immunotherapy Advisory Group, and was in the inaugural board of advisors for the George Washington University’s Milken Institute of Public Health.

 

PRIMO thanks these three outstanding women for their contributions in oncology and their commitment to improving the lives of cancer patients. We look forward to seeing the successes their continual service and dedication brings in the future.

Leave a Reply

Your email address will not be published. Required fields are marked *